Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Biomarkers, Clinical Outcomes, and Future Directions
DOI:
https://doi.org/10.48047/27ntst54Keywords:
Immunotherapy, Non–Small Cell Lung Cancer, Future DirectionsAbstract
Background: Immunotherapy has transformed the therapeutic landscape of non–small cell lung cancer (NSCLC), redefining standards of care across metastatic, locally advanced, and early-stage disease. Historically associated with poor survival outcomes, advanced NSCLC management was dominated by platinum-based chemotherapy
Downloads
References
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020. CA Cancer J Clin. 2021;71(3):209-249.
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non–small-cell lung cancer. Nature. 2018;553(7689):446-454.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
